Global Fintech Leaders Join Forces Behind Pollinate Platform
31.10.2019 14:17:00 EET | Business Wire | Press release
Pollinate, the business behind Tyl by NatWest, has launched with a growth capital investment round from a consortium of global industry leaders. Mastercard, Motive Partners and EFM Asset Management (EFM) will join RBS as both investors in, and partners to, the Pollinate business, which has raised a total of £60 million in funding to date.
Over the past decade, disruptive payment companies have challenged retail banks for ownership of their merchant relationships. Pollinate is reinventing merchant acquiring for banks, enabling them to compete effectively with these disruptors. The Pollinate technology is an innovative cloud-based platform that wraps around a bank’s legacy payment systems. The platform powers merchant and consumer digital experiences including onboarding, portals and loyalty programs, without costly and distracting platform migrations. This allows merchants to more effectively manage their businesses with digital tools and data integrations, grow their businesses by connecting with their consumers, and give back to their local communities. For banks, the Pollinate platform helps them understand and engage with their customers better and build stronger relationships with their merchants and consumers alike.
Conceived in 2017, the first deployment of the platform took place in Spring 2019 with the launch of the Tyl by NatWest merchant services business in the UK, and Pollinate is now in advanced discussions with other leading retail banks around the world.
Commenting on the announcement Alison Rose, Deputy CEO of NatWest Holdings and CEO of Commercial & Private Banking at RBS said, “I am hugely excited to announce the creation of a global merchant services company with Mastercard, Motive Partners and EFM Asset Management. Partnering with such high-quality companies, each of us bringing unique expertise and skills, allows for a truly international offering, benefitting not only our customers but the wider merchant acquiring space. We are committed to continually improving the products and experiences that we deliver to our customers, and the creation of Pollinate represents an innovative and successful approach of working with partners to do this.”
Jeff Emmanuel, Chief Investment Officer and Founder of EFM added: “As technology companies around the world are reimagining the delivery of financial services, a number of fintech ‘enablers’ have recognised the opportunity in bridging technological innovation, and the distribution scale and brand value of the largest financial institutions. Our disruptive fintech fund seeks opportunities through investment in dynamic companies which leverage their capabilities to deliver improved customer outcomes. Through combining machine learning with a unique ecosystem of data assets, Pollinate offers banks an exciting new service proposition for their customers. We are delighted to be backing this great team, and through our board participation, look forward to leveraging our network and experience in the space to maximise the opportunity.”
Pollinate is run by a team of executives from the Payments, Technology and Loyalty industries including Al Lukies CBE, Jonathan Hughes, Fiona Roach Canning, Tim Joslyn, David Beresford and Anna Moore.
Al Lukies, Pollinate CEO and Co-Founder said: “Retail banks around the world are facing common issues, but they remain the only ones in the payment chain who can connect directly with both merchants and consumers. They are therefore best placed to help SME’s process transactions, support their balance sheets, and grow their businesses, creating a virtuous circle between the bank, merchants, and consumers. As we know consumers increasingly expect a more personalised service from the businesses they interact with, regardless of their size, so at its heart Pollinate is about relationships and growth through connection - our platform enables relationships to be strengthened through fantastic digital experiences, and real-time data processing analytics and integrations.”
"Technology is making our everyday easier and more accessible. For small business owners, it's critical to separate the potential from the performance. That's why we're involved with Pollinate" said Ajay Banga, President and CEO of Mastercard. "Each of the partners brings its know-how, insights and technology to provide banks with real, tangible solutions that enables business owners to deliver the best customer experience."
Pollinate has secured important alliances with best in class brands across the payments and technology ecosystem. Available globally through the Azure cloud, the Pollinate platform utilises the best of Microsoft's big data and distributed AI platforms, threat Intelligence and authentication services to give banks and their customers access to compelling, intuitive services wherever they are. Other global partners of Pollinate, which include Mastercard, Endava, Motive Partners and EFM, ensures that Pollinate's banking clients, wherever they are based, can compete directly with the world's most innovative and disruptive companies.
“Our partner, Royal Bank of Scotland, has unique experience within the Merchant Services space and is perfectly positioned to roll out the Pollinate platform to small business across the United Kingdom. We are delighted to have a role alongside such an esteemed investor group, and we look forward to working with the Pollinate management team and our international ecosystem to building value for our partners, and ultimately SMEs and consumers.” - Rob Heyvaert, Managing Partner at Motive Partners.
ENDS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005483/en/
Contact information
Media contacts
Nicky Harrison
FieldHouse Associates
pollinate@fieldhouseassociates.com
07739338842
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
